Related references
Note: Only part of the references are listed.Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study
Beatriz Lopez-Centeno et al.
CLINICAL INFECTIOUS DISEASES (2020)
Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition
Emilie R. Elliot et al.
CLINICAL INFECTIOUS DISEASES (2019)
Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel
Matti K. Itkonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Assessment of Consistency of Drug Interaction Information in Drug Labels Among the United States, the United Kingdom, China, Japan, and Korea
Sohyun Jeong et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes
Felix Stader et al.
CLINICAL PHARMACOKINETICS (2019)
Non-AIDS-related comorbidities in people living with HIV-1 aged 50 years and older: The AGING POSITIVE study
Rosario Serrao et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV
Davide De Francesco et al.
AIDS (2019)
Prescribing issues in elderly individuals living with HIV
Catia Marzolini et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Examination of Polypharmacy Trajectories Among HIV-Positive and HIV-Negative Men in an Ongoing Longitudinal Cohort from 2004 to 2016
Deanna Ware et al.
AIDS PATIENT CARE AND STDS (2019)
Getting Older with HIV: Increasing Frequency of Comorbidities and Polypharmacy in Brazilian HIV Patients
Carlos Brites et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2019)
Polypharmacy, Hazardous Alcohol and Illicit Substance Use, and Serious Falls Among PLWH and Uninfected Comparators
Julie A. Womack et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2019)
Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling
Rajith K. R. Rajoli et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis
Charles Flexner et al.
CURRENT OPINION IN HIV AND AIDS (2019)
Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis
Amanda M. Kong et al.
AIDS PATIENT CARE AND STDS (2019)
Polypharmacy and drug drug interactions in older and younger people living with HIV: the POPPY study
Marie O. Halloran et al.
ANTIVIRAL THERAPY (2019)
A Comprehensive Framework for Physiologically-Based Pharmacokinetic Modeling in Matlab
Felix Stader et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals
Amy C. Justice et al.
AIDS (2018)
Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
Felix Stader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions
Iria Bravo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review
Daniel Atwine et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States
Parag Mahale et al.
CLINICAL INFECTIOUS DISEASES (2018)
Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites
Niloufar Marsousi et al.
CLINICAL PHARMACOKINETICS (2018)
Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: A cross-sectional study
Rafael Aguiar Maciel et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2018)
Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
Dwaipayan Mukherjee et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2018)
Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study
Mark James Rawle et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2018)
Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database
Daniel J. Ruzicka et al.
BMJ OPEN (2018)
The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65-74 years and more than 75 years
G. Guaraldi et al.
BMC GERIATRICS (2018)
Polypharmacy among HIV positive older adults on anti-retroviral therapy attending an urban clinic in Uganda
Michael Ssonko et al.
BMC GERIATRICS (2018)
Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort
Annegret Pelchen-Matthews et al.
AIDS (2018)
Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients
Clotilde Allavena et al.
PLOS ONE (2018)
Patterns of Co-occurring Comorbidities in People Living With HIV
Davide De Francesco et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Ageing with HIV: do comorbidities and polymedication drive treatment optimization?
L. Cuzin et al.
HIV MEDICINE (2017)
Use of non-antiretroviral drugs among individuals with and without HIV-infection: a Danish nationwide study
Line Rasmussen et al.
INFECTIOUS DISEASES (2017)
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection
L. Calza et al.
HIV MEDICINE (2017)
Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls
Katherine W. Kooij et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
The prescribing cascade revisited
Paula A. Rochon et al.
LANCET (2017)
A Pharmacist-Led Program to Evaluate and Reduce Polypharmacy and Potentially Inappropriate Prescribing in Older HIV-Positive Patients
Ian R. McNicholl et al.
PHARMACOTHERAPY (2017)
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Adam Trickey et al.
LANCET HIV (2017)
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the USA: A modelling study
Mikaela Smit et al.
PLOS ONE (2017)
Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran
Parag Kumar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
S. L. Ford et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir
Deborah Yoong et al.
ANNALS OF PHARMACOTHERAPY (2017)
Epidemiology of ageing with HIV: what can we learn from cohorts?
Caroline A. Sabin et al.
AIDS (2017)
Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal
Alice L. Tseng et al.
AIDS (2017)
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
Kimberly K. Scarsi et al.
CLINICAL INFECTIOUS DISEASES (2016)
Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy
Andrew Owen et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients
Hartmut B. Krentz et al.
AIDS PATIENT CARE AND STDS (2016)
Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies
Emilie R. Elliot et al.
CLINICAL MEDICINE (2016)
The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects
Ivy H. Song et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients
Leonardo Calza et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications
Catia Marzolini et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir
Rajesh Krishna et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2016)
Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population
Gilles Wandeler et al.
CURRENT OPINION IN HIV AND AIDS (2016)
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study
Amanda Mocroft et al.
LANCET HIV (2016)
An unexpected interaction between warfarin and cobicistat-boosted elvitegravir
Brittany L. Good et al.
AIDS (2015)
Cumulative Incidence of Cancer Among Persons With HIV in North America A Cohort Study
Michael J. Silverberg et al.
ANNALS OF INTERNAL MEDICINE (2015)
Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis
Kimberley Ruxton et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy
Anne-Marie Taburet et al.
CLINICAL INFECTIOUS DISEASES (2015)
HIV Infection, Cardiovascular Disease Risk Factor Profile, and Risk for Acute Myocardial Infarction
Anne-Lise Paisible et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
Sue Radcliff et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2015)
Future challenges for clinical care of an ageing population infected with HIV: a modelling study
Mikaela Smit et al.
LANCET INFECTIOUS DISEASES (2015)
Reducing Inappropriate Polypharmacy The Process of Deprescribing
Ian A. Scott et al.
JAMA INTERNAL MEDICINE (2015)
Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population
Barbara Hasse et al.
OPEN FORUM INFECTIOUS DISEASES (2015)
STOPP/START criteria for potentially inappropriate prescribing in older people: version 2
Denis O'Mahony et al.
AGE AND AGEING (2015)
Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects
Ivy Song et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Aging with HIV vs. HIV Seroconversion at Older Age: A Diverse Population with Distinct Comorbidity Profiles
Giovanni Guaraldi et al.
PLOS ONE (2015)
A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario
Claire E. Kendall et al.
BMC PUBLIC HEALTH (2014)
Impact of Clinical and Therapeutic Factors on Incident Cardiovascular and Cerebrovascular Events in a Population-Based Cohort of HIV-Infected and Non-HIV-Infected Adults
Avnish Tripathi et al.
CLINICAL CARDIOLOGY (2014)
Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEhIV Cohort Study
Judith Schouten et al.
CLINICAL INFECTIOUS DISEASES (2014)
Polypharmacy, Drug Drug Interactions, and Potentially Inappropriate Medications in Older Adults with Human Immunodeficiency Virus Infection
Meredith Greene et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2014)
Health Outcomes Associated with Polypharmacy in Community-Dwelling Older Adults: A Systematic Review
Terri R. Fried et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2014)
Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population
Magnus G. Rasch et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients
Samir K. Gupta et al.
PLOS ONE (2014)
Patient-centered care for people living with multimorbidity
Cynthia M. Boyd et al.
CURRENT OPINION IN HIV AND AIDS (2014)
Predicted metabolic drug clearance with increasing adult age
Thomas M. Polasek et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
Benoit Chauvin et al.
CLINICAL PHARMACOKINETICS (2013)
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study
J. B. Dumond et al.
HIV MEDICINE (2013)
Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management
P. Saberi et al.
HIV MEDICINE (2013)
Pharmacokinetics of Once-Daily Boosted Elvitegravir When Administered in Combination With Acid-Reducing Agents
Srinivasan Ramanathan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection: A North American Cross Cohort Analysis
Amy C. Justice et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects
Kelly E. Dooley et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population
Carol Holtzman et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2013)
Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
Hasina Samji et al.
PLOS ONE (2013)
Polypharmacy, Adverse Drug Reactions, and Geriatric Syndromes
Bhavik M. Shah et al.
CLINICS IN GERIATRIC MEDICINE (2012)
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
Danijela Gnjidic et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2012)
Pharmacotherapy Considerations in Elderly Adults
James M. Wooten
SOUTHERN MEDICAL JOURNAL (2012)
Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study
Barbara Hasse et al.
CLINICAL INFECTIOUS DISEASES (2011)
Ageing with HIV: medication use and risk for potential drug-drug interactions
Catia Marzolini et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Effect of Low-Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple-Dose Atazanavir With Ritonavir in Healthy Subjects
Li Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Age-Related Changes in Plasma Concentrations of the HIV Protease Inhibitor Lopinavir
Keith W. Crawford et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers
Jennifer J. Kiser et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Immune activation and inflammation in HIV-I infection: causes and consequences
V. Appay et al.
JOURNAL OF PATHOLOGY (2008)
Possible antiretroviral therapy-warfarin drug interaction
Patricia Pecora Fulco et al.
PHARMACOTHERAPY (2008)
Clinical consequences polypharmacy in elderly: expect the unexpected, think the unthinkable
Joel A. Salazar et al.
EXPERT OPINION ON DRUG SAFETY (2007)
Interaction between lopinavir/ritonavir and warfarin
Christine A. Hughes et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2007)
Association of suboptimal prescribing and change in lower extremity physical function over time
Mary Jo V. Pugh et al.
GERONTOLOGY (2007)
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers
MJ Glesby et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications
AA Mangoni et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Polypharmacy and medication adherence in patients with type 2 diabetes
RW Grant et al.
DIABETES CARE (2003)
Effect of number of medications on cardiovascular therapy adherence
SJ Shalansky et al.
ANNALS OF PHARMACOTHERAPY (2002)
Share Paper
